Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1875, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2020.188454
Keywords
DNA methylation; Epigenome; CRISPR/dCas9; Methylated oligonucleotide; Small non-coding RNAs; Cancer therapy
Categories
Funding
- National Key R&D Program of China [2018YFE0201604]
- National Natural Science Foundation of China [81974319]
Ask authors/readers for more resources
Abnormal DNA methylation is considered crucial for cancer initiation and development. Technologies targeting specific DNA methylation alterations in tumor-associated genes can manipulate gene epigenetic alterations more specifically and efficiently, opening a new perspective for cancer treatment.
DNA methylation abnormalities are regarded as critical event for cancer initiation and development. Tumor-associated genes encompassing aberrant DNA methylation alterations at specific locus are correlated with chromatin remodeling and dysregulation of gene expression in various malignancies. Thus, technologies designed to manipulate DNA methylation at specific loci of genome are necessary for the functional study and therapeutic application in the context of cancer management. Traditionally, the method for DNA methylation modifications demonstrates an unspecific feature, adversely causing global-genome epigenetic alterations and confusing the function of desired gene. Novel approaches for targeted DNA methylation regulation have a great advantage of manipulating gene epigenetic alterations in a more specific and efficient method. In this review, we described different targeting DNA methylation techniques, including both their advantages and limitations. Through a comprehensive understanding of these targeting tools, we hope to open a new perspective for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available